Johnson & Johnson is committed to researching targeted treatment approaches to help patients with the most aggressive forms of prostate cancer, including men with BRCA mutations.
Stay updated about genetic testing and targeted treatments for BRCA mutations in prostate cancer
Janssen Biotech, Inc., a Johnson & Johnson company, our affiliates, and our service providers will use the information that you provide to send you communications about J&J, prostate cancer and your optional requests, and to research, develop, and improve our products and services. You may unsubscribe from these communications by following the instructions in them. Our Privacy Policy further governs the use of the information you provide.
This site is published by Janssen Biotech, Inc., which is solely responsible for its contents. The material on this site is intended only as informational or as an educational aid and it is not intended to be taken as medical advice. The ultimate responsibility for patient care resides with a healthcare professional.
This information is intended for the use of patients and care partners in the United States and Puerto Rico only. Laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country.
Third party trademarks used herein are trademarks of their respective owners.
Last updated November 2024 | cp-388273v4